B
Brent A. Neuschwander-Tetri
Researcher at Saint Louis University
Publications - 203
Citations - 29303
Brent A. Neuschwander-Tetri is an academic researcher from Saint Louis University. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Steatohepatitis. The author has an hindex of 58, co-authored 183 publications receiving 23528 citations. Previous affiliations of Brent A. Neuschwander-Tetri include University of Pittsburgh & University of Bari.
Papers
More filters
metabolic, biochemical and histopathological indices of nonalcoholic
James L. Trevaskis,Peter S. Griffin,Carrie Wittmer,Brent A. Neuschwander-Tetri,Elizabeth,M. Brunt,Carrie S. Dolman,Mary Erickson,James Napora,David G. Parkes +9 more
Journal ArticleDOI
Interactions between Bile Acids and Nuclear Receptors and Their Effects on Lipid Metabolism and Liver Diseases
TL;DR: The identification of bile acid-activated nuclear receptor farnesoid X receptor (FXR) and cell surface G-protein-coupled receptor TGR5 has significantly advanced the authors' understanding on how bile Acid signaling regulates cellular metabolism in health and disease.
Journal ArticleDOI
Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
Wei Shen,Michael S. Middleton,Guilherme Moura Cunha,Timoteo Delgado,Tanya Wolfson,Anthony Gamst,Kathryn J. Fowler,Adina Alazraki,Andrew T. Trout,Michael A. Ohliger,Shetal N. Shah,Mustafa R. Bashir,David E. Kleiner,Rohit Loomba,Brent A. Neuschwander-Tetri,Arun J. Sanyal,Jane Zhou,Claude B. Sirlin,Joel E. Lavine +18 more
TL;DR: In this paper , a secondary analysis of prospectively acquired data from the multicenter, randomized, placebo-controlled FLINT trial investigated the relationship between reduction in adipose tissue compartment volumes and hepatic histologic improvement.
Journal ArticleDOI
LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use
Brent A. Neuschwander-Tetri,Arun J. Sanyal,R. Loomba,Naga Chalasani,Kris V. Kowdley,M. Abdelmalek,Elizabeth M. Brunt,David Shapiro +7 more
TL;DR: Preliminary efficacy evaluations justified continued enrollment in the 300mg/kg arm but not in the 200mg/ kg low dose arm (closed by amendment).
Journal ArticleDOI
Fibrosis Progression Rate in Biopsy-proven Nonalcoholic Fatty Liver Disease among People with Diabetes versus People without Diabetes: A Multicenter Study.
Daniel Q. Huang,Laura A. Wilson,Cynthia Behling,David E. Kleiner,Kris V. Kowdley,Srinivasan Dasarathy,Maral Amangurbanova,Norah A. Terrault,Anna Mae Diehl,Naga Chalasani,Brent A. Neuschwander-Tetri,Arun J. Sanyal,James Tonascia,Rohit Loomba +13 more
TL;DR: In this paper , the time to fibrosis progression in people with Type 2 diabetes mellitus (T2DM) versus people without T2DM was assessed in a large, multicenter, study of people with NAFLD who had paired liver biopsies.